If someone can only look at the issue in such generic terms and comes up with such a deeply flawed analysis that they missperceive one of the most positive events that can happen to a drug candidate at this stage [[the toxicity is SO LOW that preliminary tox tests are required. OH< and BTW: there's a strong possibility that the drug may qualify for a FAST TRACK. And the time to the end of clinical trials will be much FASTER]]
Perhaps some are investing in a sector where their understanding is dangerously inadequate.
BTW: the OTHER major qualification for a fast track (other than very low toxicity) is high efficacy, which NNVC's drug also appears to have "in spades".
PS!!! Also note that getting a "fast track" very greatly speeds up the process of clinical trials IN ADDITION to all the other factors. (shouldn't have to point that out, but considering past posts .....)
News 
Market Data 
Discover 
